Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMMBA70)

Drug Name

CALYSTEGINE B2 Drug Info

Synonyms

Calystegine B2; (1S,2R,3S,4R,5S)-8-AZABICYCLO[3.2.1]OCTANE-1,2,3,4-TETROL; 8-Aza-bicyclo[3.2.1]octane-1,2,3,4-tetraol; (1R,2S,3R,4S,5R)-8-azabicyclo[3.2.1]octane-1,2,3,4-tetrol; 127414-85-1; CGB; Calystegine B(2); 2cbv; 1,2,3,4-Tetrahydroxy-nor-tropane; CID124434; SCHEMBL2435745; CHEMBL526330; BDBM36389; MolPort-006-169-861; ZINC12504453; (2-endo,3-exo,4-endo)-8-Azabicyclo(3.2.1)octane-1,2,3,4-tetrol; AKOS030531595; DB04658; LS-190985; W-200999; 8-Aza-bicyclo[3.2.1]octane-1,2,3,4-tetraol, 14

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

PubChem CID: 124434
CAS Number: CAS 127414-85-1
TTD Drug ID: DMMBA70

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Alpha-galactosidase A (GLA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Pegunigalsidase alfa	DMOUW65	Fabry disease	5C56.01	Approved	[2]
Migalastat	DMFIQ2H	Fabry disease	5C56.01	Approved	[3]
AVR-RD-01	DMC1XHK	Fabry disease	5C56.01	Phase 1/2	[4]
ST-920	DMOJIPG	Fabry disease	5C56.01	Phase 1/2	[5]
4D-310	DMNG59Y	Fabry disease	5C56.01	Phase 1/2	[6]
isaralgagene civaparvovec	DM5SSPZ	Fabry disease	5C56.01	Phase 1/2	[7]
Alpha-D-Mannose	DMF5DLW	Discovery agent	N.A.	Investigative	[8]
Fucose	DMAHMSV	N. A.	N. A.	Investigative	[8]
2,5-dideoxy-2,5-imino-D-altritol	DMI1O54	Discovery agent	N.A.	Investigative	[9]
Beta-1-C-Butyl-1-deoxygalactonojirimycin	DMMKDEZ	Discovery agent	N.A.	Investigative	[9]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Alpha-galactosidase A (GLA)	TTIS03D	AGAL_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	Identification of the glycosidase inhibitors swainsonine and calystegine B2 in Weir vine (Ipomoea sp. Q6 [aff. calobra]) and correlation with toxicity. J Nat Prod. 1995 Jun;58(6):878-86.
2	Characterization of a chemically modified plant cell culture expressed human alpha-Galactosidase-A enzyme for treatment of Fabry disease. Mol Genet Metab. 2015 Feb;114(2):259-67.
3	AT-1001: a high-affinity alpha3beta4 nAChR ligand with novel nicotine-suppressive pharmacology. Br J Pharmacol. 2015 Apr;172(7):1834-45.
4	Clinical pipeline report, company report or official report of Avrobio.
5	AAV2/6 Gene Therapy in a Murine Model of Fabry Disease Results in Supraphysiological Enzyme Activity and Effective Substrate Reduction. Mol Ther Methods Clin Dev. 2020 Jul 9;18:607-619.
6	Clinical pipeline report, company report or official report of 4D Molecular Therapeutics
7	ClinicalTrials.gov (NCT04046224) A Phase I/II, Multicenter, Open-Label, Single-Dose, Dose-Ranging Study to Assess the Safety and Tolerability of ST-920, an AAV2/6 Human Alpha Galactosidase A Gene Therapy, in Subjects With Fabry Disease (STAAR). U.S.National Institutes of Health.
8	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
9	2,5-Dideoxy-2,5-imino-d-altritol as a new class of pharmacological chaperone for Fabry disease. Bioorg Med Chem. 2010 Jun 1;18(11):3790-4.